TMS Co., Ltd. engages in the research and development, manufacture, and sale of drug products, quasi-drugs, drug substances, medical devices, and medical commodities. The company is developing TMS-007, a stachybotrys microspora triprenyl phenol (SMTP) congener with prothrombolytic and anti-inflammatory/antioxidative activities, which has completed Phase 2a clinical trials for acute ischemic stroke treatment; and TMS-008, an SMTP congener with anti-inflammatory/antioxidative activities under nonclinical development for inflammatory complications, such as acute kidney injury and cancer cachexia. It is also developing TMS-009, a product candidate in preclinical development. The company has a collaboration with Hokkaido University and Kanazawa University to evaluate the potential of the drug candidate compounds as novel drugs, as well as a joint research agreement with Teikyo University to identify biomarkers for renal function and a strategic alliance with Ji Xing Pharmaceuticals Limited. TMS Co., Ltd. was incorporated in 2005 and is headquartered in Fuchu, Japan.